Tesamorelin
Detailed Product description
Tesamorelin – Growth Hormone Releasing Hormone (GHRH) Analog Research Compound
Discover Tesamorelin – a high-purity synthetic growth hormone releasing hormone (GHRH) analog designed for advanced laboratory research. This single-compound formulation is commonly used in controlled scientific studies exploring growth hormone secretion, endocrine signaling pathways, and metabolic research.
Key Benefits
- High-purity research compound ideal for precise laboratory protocols
- Provides a stable and consistent option for studies involving GH axis modulation
- Designed for researchers requiring reliable GHRH analog performance
- Supports convenient handling and storage in scientific applications
- Offers a well-characterized compound for complex research workflows
How It Works
Tesamorelin functions as a GHRH analog, stimulating the release of growth hormone in controlled research environments. This formulation allows researchers to study GH-related pathways with a single, well-defined research compound.
Research Snapshot
- Based on established research compounds with decades of individual study data
- Popular in scientific communities exploring GHRH analogs and GH axis modulation
- Preclinical and observational data available for the compound
- Widely used in research settings requiring targeted endocrine investigations
Why Choose Our Tesamorelin?
- Third-party tested purity
- GMP-compliant sourcing
- Transparent research-grade quality
Add to Cart now. Limited supply — secure yours today!
For research/educational purposes only.
Additional Info
- Color: White
- Purity: >99%
ADD THE ESSENTIALS
Frequently Bought Together
Reta GLP-3
GHK-CU
Reta GLP-3
CJC-1295 No DAC + Ipamorelin
BPC-157 + TB-500
Reta GLP-3
KLOW
"Fonctionne bien"
★★★★★
Lei
Reta GLP-3 • 02 juin 2026"Excellente qualité. Je recommande"
★★★★★
Majdouline
Reta GLP-3 • 04 juin 2026"Franchement je recommande rapidité et efficacité."
★★★★★
HINDE
Reta GLP-3 • 18 juin 2026"Très sérieux envoie rapide et soigné je recommande"
★★★★★
stephanie
Reta GLP-3 • 22 juin 2026